Document Detail

Obesity, adiposity, and lengthening of the QT interval: improvement after weight loss.
MedLine Citation:
PMID:  8910099     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To determine the prevalence of QT interval prolongation in patients referred to an outpatient clinic for treatment of obesity; and to describe the change in the QT interval during rapid weight loss with a very-low-calorie diet.
DESIGN: Retrospective and prospective review of charts and electrocardiograms.
SUBJECTS: Five hundred twenty-two obese patients (411 female, 112 males) with a mean age 44 (18-78 y) and a mean initial weight of 116 kg (63-285 kg) completing 26 weeks of treatment between September, 1989 through to December, 1993.
MEASUREMENTS: We reviewed the EKGs of all patients and serially monitored the QTc if greater than 0.44 s or if more than 23 kg was lost during treatment. The QTc interval was calculated with Bazzett's formula using both a manual method and an automated software program. In some patients, body composition was measured by hydrodensitometry.
RESULTS: The QTc interval before treatment was 0.42 +/- 0.026 s by manual measurement and 0.41 +/- 0.021 s by automated measurement. Forty-one to 53% of patients showed a QTc interval of greater than 0.42 s and 10-24% demonstrated moderate prolongation (> 0.44 s). In those patients for whom repeat EKG were performed, QTc showed shortening with weight loss by both methods (mean +/- s.e. of 0.42 +/- 0.003 to 0.41 +/- 0.003 s, P < 0.01 manually and 0.41 +/- 0.003 to 0.40 +/- 0.003 s, p < 0.005 by automated program). Analyses were repeated excluding 179 patients with a cardiovascular-related diagnosis or intraventricular block and the results were similar. By regression analysis, gender and fat mass (FM) percentage above normal predicted the QTc.
CONCLUSIONS: QT Interval prolongation is common in obesity. For each 50% increase in FM% above normal, there is a 5 ms increase in the QTc above a 'normal' upper limit of 0.40 and 0.38 s in women and men, respectively. Moreover, the QT interval shortens with weight loss. This change may represent an additional benefit of weight loss along with the improvement in other cardiovascular risk factors.
M J Carella; S L Mantz; D R Rovner; P W Willis; V V Gossain; R R Bouknight; G S Ferenchick
Related Documents :
21112669 - A case-control study of cutaneous signs in adult patients with marfan disease: diagnost...
1582019 - Patterns of serological markers for cellular immune activation in patients with dilated...
10371699 - Cd36 deficiency has little influence on the pathophysiology of hypertrophic cardiomyopa...
7540289 - Cardiac dysrhythmias in children with idiopathic dilated or hypertrophic cardiomyopathy.
17600039 - A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and rec...
2332929 - The role of late potentials in the assessment of myocardial degeneration in idiopathic ...
2447209 - Elastase-1 vs trypsin, lipase and amylase serum levels in pancreatic diseases.
17114879 - Exercise testing in asymptomatic aortic stenosis.
8425119 - Chlorpromazine-induced psychosis after brain injury.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity     Volume:  20     ISSN:  -     ISO Abbreviation:  Int. J. Obes. Relat. Metab. Disord.     Publication Date:  1996 Oct 
Date Detail:
Created Date:  1996-12-27     Completed Date:  1996-12-27     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  9313169     Medline TA:  Int J Obes Relat Metab Disord     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  938-42     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adipose Tissue*
Blood Glucose / metabolism
Blood Pressure
Body Composition*
Cardiovascular Diseases / etiology
Lipids / blood
Middle Aged
Obesity / complications,  physiopathology,  therapy*
Risk Factors
Weight Loss*
Reg. No./Substance:
0/Blood Glucose; 0/Lipids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Publication bias in obesity treatment trials?
Next Document:  Obesity, diet and restrained eating in a Mediterranean population.